GIBF commits $10 million in funding to Nectin Therapeutics for the development of innovative first-in-class immunotherapies and antibody-drug conjugates.

May 8th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Edgewise Therapeutics has administered the initial dose to a participant in the Phase 2 CIRRUS-HCM study, evaluating EDG-7500 in patients with Obstructive Hypertrophic Cardiomyopathy (HCM).

Immune checkpoints are a class of regulatory molecules in the immune system that are expressed on immune cells such as T cells and can modulate the intensity and duration of immune responses.

Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.

Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.

HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.

Diabetic macular edema (DME) is an eye complication related to diabetes, primarily affecting the macula region of the eye.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

May 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.

4.29-5.5 Global Drug R&D Progress & Pharmaceutical Transaction Trends.